298 related articles for article (PubMed ID: 34106455)
21. Pembrolizumab: first global approval.
Poole RM
Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
[TBL] [Abstract][Full Text] [Related]
22. Dostarlimab: A Review.
Costa B; Vale N
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 35892341
[TBL] [Abstract][Full Text] [Related]
23. Programmed death protein 1 inhibitors making inroads in multiple cancers.
Brower V
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
[No Abstract] [Full Text] [Related]
24. Envafolimab: First Approval.
Markham A
Drugs; 2022 Feb; 82(2):235-240. PubMed ID: 35122636
[TBL] [Abstract][Full Text] [Related]
25. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL-2 stimulation data.
Austin D; Melhem M; Gandhi Y; Lu S; Visser S
CPT Pharmacometrics Syst Pharmacol; 2023 Jan; 12(1):87-94. PubMed ID: 36317409
[TBL] [Abstract][Full Text] [Related]
27. Dostarlimab for the treatment of endometrium cancer and other solid tumors.
Rubio-Pérez J; Hernández R; Hernández T; Doger B; Casado V; Moreno V
Drugs Today (Barc); 2021 Mar; 57(3):187-197. PubMed ID: 33729216
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
[TBL] [Abstract][Full Text] [Related]
29. Amivantamab: First Approval.
Syed YY
Drugs; 2021 Jul; 81(11):1349-1353. PubMed ID: 34292533
[TBL] [Abstract][Full Text] [Related]
30. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
Yu Y
Front Med; 2018 Apr; 12(2):229-235. PubMed ID: 29209918
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
33. Dostarlimab for the treatment of advanced endometrial cancer.
Redondo A; Gallego A; Mendiola M
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
[TBL] [Abstract][Full Text] [Related]
34. Ocrelizumab: First Global Approval.
Frampton JE
Drugs; 2017 Jun; 77(9):1035-1041. PubMed ID: 28523586
[TBL] [Abstract][Full Text] [Related]
35. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
37. Tislelizumab: First Approval.
Lee A; Keam SJ
Drugs; 2020 Apr; 80(6):617-624. PubMed ID: 32185681
[TBL] [Abstract][Full Text] [Related]
38. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
39. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
Fernández A
Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
[TBL] [Abstract][Full Text] [Related]
40. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
